XERIS BIOPHARMA HOLDINGS INC (XERS) Stock Fundamental Analysis
NASDAQ:XERS • US98422E1038
6.82 USD
-0.09 (-1.3%)
At close: Feb 13, 2026
6.82 USD
0 (0%)
After Hours: 2/13/2026, 8:00:02 PM
Overall XERS gets a fundamental rating of 4 out of 10. We evaluated XERS against 191 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of XERS have multiple concerns. XERS is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
- In the past year XERS has reported negative net income.
- XERS had a positive operating cash flow in the past year.
- In the past 5 years XERS always reported negative net income.
- In the past 5 years XERS always reported negative operating cash flow.
1.2 Ratios
- XERS has a better Return On Assets (-4.22%) than 73.82% of its industry peers.
- XERS's Return On Invested Capital of 3.05% is amongst the best of the industry. XERS outperforms 80.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.22% | ||
| ROE | N/A | ||
| ROIC | 3.05% |
ROA(3y)-21.25%
ROA(5y)-32.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- XERS has a better Operating Margin (3.68%) than 78.53% of its industry peers.
- XERS has a better Gross Margin (84.56%) than 87.96% of its industry peers.
- In the last couple of years the Gross Margin of XERS has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.68% | ||
| PM (TTM) | N/A | ||
| GM | 84.56% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.81%
GM growth 5Y14.98%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so XERS is destroying value.
- Compared to 1 year ago, XERS has more shares outstanding
- XERS has more shares outstanding than it did 5 years ago.
- XERS has a worse debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of 0.43, we must say that XERS is in the distress zone and has some risk of bankruptcy.
- XERS's Altman-Z score of 0.43 is in line compared to the rest of the industry. XERS outperforms 49.74% of its industry peers.
- The Debt to FCF ratio of XERS is 22.00, which is on the high side as it means it would take XERS, 22.00 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of XERS (22.00) is better than 74.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 22 | ||
| Altman-Z | 0.43 |
ROIC/WACC0.3
WACC10.03%
2.3 Liquidity
- XERS has a Current Ratio of 1.93. This is a normal value and indicates that XERS is financially healthy and should not expect problems in meeting its short term obligations.
- XERS has a worse Current ratio (1.93) than 63.35% of its industry peers.
- XERS has a Quick Ratio of 1.35. This is a normal value and indicates that XERS is financially healthy and should not expect problems in meeting its short term obligations.
- The Quick ratio of XERS (1.35) is worse than 68.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.35 |
3. Growth
3.1 Past
- XERS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 77.78%, which is quite impressive.
- The Revenue has grown by 42.05% in the past year. This is a very strong growth!
- XERS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 137.28% yearly.
EPS 1Y (TTM)77.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)42.05%
Revenue growth 3Y59.98%
Revenue growth 5Y137.28%
Sales Q2Q%37.06%
3.2 Future
- Based on estimates for the next years, XERS will show a very strong growth in Earnings Per Share. The EPS will grow by 34.91% on average per year.
- XERS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.22% yearly.
EPS Next Y88.59%
EPS Next 2Y57.71%
EPS Next 3Y43.51%
EPS Next 5Y34.91%
Revenue Next Year43.35%
Revenue Next 2Y35.31%
Revenue Next 3Y29.39%
Revenue Next 5Y23.22%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for XERS. In the last year negative earnings were reported.
- Based on the Price/Forward Earnings ratio of 36.84, the valuation of XERS can be described as expensive.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of XERS indicates a somewhat cheap valuation: XERS is cheaper than 69.11% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 27.96, XERS is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 36.84 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of XERS indicates a somewhat cheap valuation: XERS is cheaper than 76.96% of the companies listed in the same industry.
- Based on the Price/Free Cash Flow ratio, XERS is valued a bit cheaper than 75.39% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 113.44 | ||
| EV/EBITDA | 59.3 |
4.3 Compensation for Growth
- XERS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- XERS's earnings are expected to grow with 43.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y57.71%
EPS Next 3Y43.51%
5. Dividend
5.1 Amount
- XERS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
6.82
-0.09 (-1.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-04 2026-03-04/amc
Inst Owners59.48%
Inst Owner Change-1.43%
Ins Owners2.63%
Ins Owner Change-0.3%
Market Cap1.13B
Revenue(TTM)266.14M
Net Income(TTM)-15.64M
Analysts84.62
Price Target11.37 (66.72%)
Short Float %10.6%
Short Ratio8.08
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-17.83%
Min EPS beat(2)-100%
Max EPS beat(2)64.35%
EPS beat(4)2
Avg EPS beat(4)1.9%
Min EPS beat(4)-100%
Max EPS beat(4)64.35%
EPS beat(8)3
Avg EPS beat(8)-2.73%
EPS beat(12)6
Avg EPS beat(12)5.17%
EPS beat(16)9
Avg EPS beat(16)1.29%
Revenue beat(2)1
Avg Revenue beat(2)3.46%
Min Revenue beat(2)-1.7%
Max Revenue beat(2)8.61%
Revenue beat(4)3
Avg Revenue beat(4)2.66%
Min Revenue beat(4)-1.7%
Max Revenue beat(4)8.61%
Revenue beat(8)5
Avg Revenue beat(8)1.52%
Revenue beat(12)9
Avg Revenue beat(12)3.74%
Revenue beat(16)11
Avg Revenue beat(16)2.82%
PT rev (1m)0%
PT rev (3m)23.81%
EPS NQ rev (1m)15.79%
EPS NQ rev (3m)46.67%
EPS NY rev (1m)1.92%
EPS NY rev (3m)-70%
Revenue NQ rev (1m)1.21%
Revenue NQ rev (3m)0.12%
Revenue NY rev (1m)0.28%
Revenue NY rev (3m)0.61%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 36.84 | ||
| P/S | 4.25 | ||
| P/FCF | 113.44 | ||
| P/OCF | 107.18 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 59.3 |
EPS(TTM)-0.1
EYN/A
EPS(NY)0.19
Fwd EY2.71%
FCF(TTM)0.06
FCFY0.88%
OCF(TTM)0.06
OCFY0.93%
SpS1.6
BVpS-0.01
TBVpS-0.69
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.22% | ||
| ROE | N/A | ||
| ROCE | 3.86% | ||
| ROIC | 3.05% | ||
| ROICexc | 4.77% | ||
| ROICexgc | 15.89% | ||
| OM | 3.68% | ||
| PM (TTM) | N/A | ||
| GM | 84.56% | ||
| FCFM | 3.75% |
ROA(3y)-21.25%
ROA(5y)-32.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.81%
GM growth 5Y14.98%
F-Score7
Asset Turnover0.72
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 22 | ||
| Debt/EBITDA | 10.21 | ||
| Cap/Depr | 4.99% | ||
| Cap/Sales | 0.22% | ||
| Interest Coverage | 0.37 | ||
| Cash Conversion | 49.13% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z | 0.43 |
F-Score7
WACC10.03%
ROIC/WACC0.3
Cap/Depr(3y)9.93%
Cap/Depr(5y)22.72%
Cap/Sales(3y)0.76%
Cap/Sales(5y)1.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y88.59%
EPS Next 2Y57.71%
EPS Next 3Y43.51%
EPS Next 5Y34.91%
Revenue 1Y (TTM)42.05%
Revenue growth 3Y59.98%
Revenue growth 5Y137.28%
Sales Q2Q%37.06%
Revenue Next Year43.35%
Revenue Next 2Y35.31%
Revenue Next 3Y29.39%
Revenue Next 5Y23.22%
EBIT growth 1Y121.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year242.35%
EBIT Next 3Y63.41%
EBIT Next 5Y46.27%
FCF growth 1Y113.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y114.95%
OCF growth 3YN/A
OCF growth 5YN/A
XERIS BIOPHARMA HOLDINGS INC / XERS FAQ
Can you provide the ChartMill fundamental rating for XERIS BIOPHARMA HOLDINGS INC?
ChartMill assigns a fundamental rating of 4 / 10 to XERS.
Can you provide the valuation status for XERIS BIOPHARMA HOLDINGS INC?
ChartMill assigns a valuation rating of 4 / 10 to XERIS BIOPHARMA HOLDINGS INC (XERS). This can be considered as Fairly Valued.
How profitable is XERIS BIOPHARMA HOLDINGS INC (XERS) stock?
XERIS BIOPHARMA HOLDINGS INC (XERS) has a profitability rating of 3 / 10.
How financially healthy is XERIS BIOPHARMA HOLDINGS INC?
The financial health rating of XERIS BIOPHARMA HOLDINGS INC (XERS) is 2 / 10.